Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

@article{Madlensky2011TamoxifenMC,
  title={Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.},
  author={Lisa Madlensky and Loki Natarajan and Simone M Tchu and Ming-zhi Pu and Joanne E. Mortimer and Shirley W. Flatt and D. Michele Nikoloff and Grant Hillman and Marcel R Fontecha and Hashtroudi Lawrence and Barbara A Parker and Alan H. B. Wu and John P Pierce},
  journal={Clinical pharmacology and therapeutics},
  year={2011},
  volume={89 5},
  pages={
          718-25
        }
}
We explored whether breast cancer outcomes are associated with endoxifen and other metabolites of tamoxifen and examined potential correlates of endoxifen concentration levels in serum including cytochrome P450 2D6 (CYP2D6) metabolizer phenotype and body mass index (BMI). Concentration levels of tamoxifen, endoxifen, 4-hydroxytamoxifen (4OH-tamoxifen), and N-desmethyltamoxifen (ND-tamoxifen) were measured from samples taken from 1,370 patients with estrogen receptor (ER)-positive breast cancer… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 124 CITATIONS, ESTIMATED 53% COVERAGE

235 Citations

02040'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 235 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Survival Analysis Using S: Analysis of Time-to-Event Data

  • M. Tableman, JS. Kim
  • Boca Raton: Chapman
  • 2004
Highly Influential
3 Excerpts

Testing fit of genotype frequencies to HardyWeinberg proportions

  • G. Thomson, HM. Torres, AK Lancaster
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…